Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

6 in Phase 3

Quick facts

Phase 3 pipeline

Arm A: FOLFIRI or FOLFOX + Bevacizumab · Oncology
FOLFIRI or FOLFOX chemotherapy regimens combined with bevacizumab inhibit tumor cell division and angiogenesis to treat colorectal cancer.
Arm B: FOLFIRI or FOLFOX · Oncology
FOLFIRI and FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluorouracil-based cytotoxic activity, with irinotecan targeting topoisomerase I or oxaliplatin targeting DNA cross-linking.
Arm D: FOLFIRI or FOLFOX plus CETUXIMAB · Oncology
This combination regimen uses chemotherapy (FOLFIRI or FOLFOX) to kill rapidly dividing cancer cells, combined with cetuximab, a monoclonal antibody that blocks epidermal growth factor receptor (EGFR) signaling to prevent tumor growth.
High intensity therapies · Oncology
High intensity therapies refer to aggressive, multi-modal treatment regimens combining chemotherapy, radiation, and/or targeted agents to maximize tumor control.
IL2 · Oncology
IL-2 (interleukin-2) is a cytokine that activates and expands T cells and natural killer cells to enhance anti-tumor immune responses.
Low intensity therapies · Oncology
Low intensity therapies refer to reduced-dose or less aggressive treatment regimens designed to maintain efficacy while minimizing toxicity in cancer patients.

Phase 2 pipeline

[177Lu]Lu-PSMA I&T
177Lu-PSMA · Oncology
177Lu-PSMA is a radioligand therapy that delivers lutetium-177, a beta-emitting radioisotope, directly to prostate-specific membrane antigen (PSMA) on cancer cells, causing targeted cell death.
Anti-CD22 Immunotoxin · Oncology
An immunotoxin that binds to CD22 on B-cell lymphomas and delivers a cytotoxic payload to kill malignant cells.
arm 4: DC Vaccine
Autologous DC vaccine · Oncology
Stimulates an immune response against cancer cells
PRRT every 5 weeks
PRRT every 8-10 weeks

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

Frequently asked questions about Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS

What is Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS's pipeline?

Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS has 6 drugs in Phase 3, 7 in Phase 2, 0 in Phase 1. Late-stage candidates include Arm A: FOLFIRI or FOLFOX + Bevacizumab, Arm B: FOLFIRI or FOLFOX, Arm D: FOLFIRI or FOLFOX plus CETUXIMAB, High intensity therapies.

Sector hub: All tracked pharma companies